New Alzheimer's Drug Diranersen Shows Promise in Reducing Tau and Slowing Cognitive Decline

Summary

Scientists at the Alzheimer's Association International Conference in London have reported encouraging results in testing for and reducing levels of tau protein, a key contributor to Alzheimer's disease. A study by Biogen on the drug diranersen showed a 50%-65% reduction in tau in patients' brains and slowed cognitive decline by up to 50%.